Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 10
2016 19
2017 28
2018 30
2019 21
2020 24
2021 16
2022 11
2023 7
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31601704

136 results

Results by year

Filters applied: . Clear all
Page 1
[68Ga]Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for Detection of Cancer: Initial Evaluation and Comparison with [68Ga]Ga-PSMA-11 in Prostate Cancer Patients Presenting with Biochemical Recurrence.
Green MA, Hutchins GD, Bahler CD, Tann M, Mathias CJ, Territo W, Sims J, Polson H, Alexoff D, Eckelman WC, Kung HF, Fletcher JW. Green MA, et al. Mol Imaging Biol. 2020 Jun;22(3):752-763. doi: 10.1007/s11307-019-01421-7. Mol Imaging Biol. 2020. PMID: 31429050 Free PMC article.
The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, Eisenhut M, Kübler W, Holland-Letz T, Giesel FL, Mier W, Kopka K, Haberkorn U. Afshar-Oromieh A, et al. J Nucl Med. 2015 Nov;56(11):1697-705. doi: 10.2967/jnumed.115.161299. Epub 2015 Aug 20. J Nucl Med. 2015. PMID: 26294298 Free article.
Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.
Uprimny C, Kroiss AS, Fritz J, Decristoforo C, Kendler D, von Guggenberg E, Nilica B, Maffey-Steffan J, di Santo G, Bektic J, Horninger W, Virgolini IJ. Uprimny C, et al. Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1647-1655. doi: 10.1007/s00259-017-3743-z. Epub 2017 Jun 6. Eur J Nucl Med Mol Imaging. 2017. PMID: 28589253
Whole-Body Integrated [68Ga]PSMA-11-PET/MR Imaging in Patients with Recurrent Prostate Cancer: Comparison with Whole-Body PET/CT as the Standard of Reference.
Guberina N, Hetkamp P, Ruebben H, Fendler W, Grueneisen J, Suntharalingam S, Kirchner J, Puellen L, Harke N, Radtke JP, Umutlu L, Hadaschik BA, Herrmann K, Forsting M, Wetter A. Guberina N, et al. Mol Imaging Biol. 2020 Jun;22(3):788-796. doi: 10.1007/s11307-019-01424-4. Mol Imaging Biol. 2020. PMID: 31482413
The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.
Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, Eisenhut M, Boxler S, Hadaschik BA, Kratochwil C, Weichert W, Kopka K, Debus J, Haberkorn U. Afshar-Oromieh A, et al. Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):197-209. doi: 10.1007/s00259-014-2949-6. Epub 2014 Nov 20. Eur J Nucl Med Mol Imaging. 2015. PMID: 25411132 Free PMC article.
136 results